A Phase 4 interventional study of Fingolimod and Interferon beta - 1a (IFN) in Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 26 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 7th largest by enrollment, is one of 4 that started in 2012, is one of 14 in phase 4, and was the 9th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 298 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 142 across the 19 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis: 1 open now, 4 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 7th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2012, is one of 15 in phase 4, and was the 13th registered.
Novartis’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Among Novartis’s 34 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (fingolimod) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 0.5 mg orally once a day.
Drug: Fingolimod
Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.
Drug: Interferon beta - 1a (IFN) · Drug: Glatiramer acetate (GA)
0.5 mg orally once a day
Also known as: Gilenya
44 mcg subcutaneously three times a week
Also known as: Rebif
20 mg subcutaneously once a day
Also known as: Copaxone
Change in Patient-reported Treatment Satisfaction
The Treatment Satisfaction Questionnaire for Medication (TSQM) contains 14 items assessing the following 4 domains: effectiveness (items 1 - 3), side effects (items 4 - 8), convenience (items 9 - 11) and global satisfaction (items 12 - 14). The primary outcome was measured on the global satisfaction domain. Item 12 scored as 1 (not at all confident) to 5 (extremely confident); item 13 scored as 1 (not at all certain) to 5 (extremely certain); and item 14 scored as 1 (extremely dissatisfied) to 7 (extremely satisfied). Responses to items were summed and transformed: specifically, TSQM v 1.4 domain scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.
Time frame: Baseline, 6 months
Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death
Participants were monitored for adverse events, serious adverse events and death throughout the study.
Time frame: 6 months
Changes in Patient-reported Effectiveness, Side Effects and Convenience
TSQM v 1.4 domains for effectiveness, side effects and convenience were used to evaluate this outcome. The effectiveness domain for items 1 - 3 was scored as: 1 (extremely dissatisfied) to 7 (extremely satisfied). For the side effects domain, item 4 scored as 0(no) or 1(yes); item 5 scored as 1 (extremely bothersome) to 5 (not at all bothersome); and items 6 - 8 scored as 1 (a great deal) to 5 (not at all). For the convenience domain, items 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy), and item 11 scored as 1 (extremely inconvenient) to 7 (extremely convenient). For each domain, scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.
Time frame: Baseline, 6 months
Change in Patient-reported Depression
The Beck Depression Inventory (BDI-I) scale was used to measure this outcome. The scale consists of 21 items to assess the intensity of depression in clinical and normal patients. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each item was scored from 0 - 3. If more than one score was provided for an item, the maximum score was considered the item score. The total score was calculated as the sum of all individual items and then compared to a key to determine the depression's severity. The standard key ranges were: 0 - 9 indicated minimal depression; 10 - 18 indicated mild depression; 19 - 29 indicated moderate depression and 30 - 63 indicated severe depression. Higher total scores indicate more severe depressive symptoms.
Time frame: Baseline, 6 months
Change in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Acute (SF-36 v2 Acute)
The SF-36 is a health-related quality of life instrument used in numerous disease states, including MS (Brazier et al 1992). It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each domain was scored by adding the individual items from the domain and transforming the resulting scores into a 0 to 100 scale with higher scores indicating better health status or functioning.
Time frame: Baseline, 6 months
Participants at screening received standard DMT with either interferon beta-1a or glatiramer acetate from day -30 to day -1.
| Milestone | Fingolimod | Standard Disease Modifying Therapy (DMT) |
|---|---|---|
| Started | 230 | 68 |
| Safety set | 230 | 64 |
| Full analysis set | 229 | 62 |
| Completed | 218 | 58 |
| Not completed | 12 | 10 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 7 |
| Withdrew: Adverse event | 7 | 3 |
The Treatment Satisfaction Questionnaire for Medication (TSQM) contains 14 items assessing the following 4 domains: effectiveness (items 1 - 3), side effects (items 4 - 8), convenience (items 9 - 11) and global satisfaction (items 12 - 14). The primary outcome was measured on the global satisfaction domain. Item 12 scored as 1 (not at all confident) to 5 (extremely confident); item 13 scored as 1 (not at all certain) to 5 (extremely certain); and item 14 scored as 1 (extremely dissatisfied) to 7 (extremely satisfied). Responses to items were summed and transformed: specifically, TSQM v 1.4 domain scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.
| scores on a scale | Fingolimod | Standard Disease Modifying Therapy (DMT) |
|---|---|---|
| Change in Patient-reported Treatment Satisfaction | 22.69 ± 28.12 | 13.92 ± 30.63 |
Participants were monitored for adverse events, serious adverse events and death throughout the study.
| Participants | Fingolimod | Standard Disease Modifying Therapy (DMT) |
|---|---|---|
| Adverse events (serious and non-serious) | 73 | 26 |
| Serious adverse events | 2 | 0 |
| Deaths | 0 | 0 |
TSQM v 1.4 domains for effectiveness, side effects and convenience were used to evaluate this outcome. The effectiveness domain for items 1 - 3 was scored as: 1 (extremely dissatisfied) to 7 (extremely satisfied). For the side effects domain, item 4 scored as 0(no) or 1(yes); item 5 scored as 1 (extremely bothersome) to 5 (not at all bothersome); and items 6 - 8 scored as 1 (a great deal) to 5 (not at all). For the convenience domain, items 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy), and item 11 scored as 1 (extremely inconvenient) to 7 (extremely convenient). For each domain, scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.
| scores on a scale | Fingolimod | Standard Disease Modifying Therapy (DMT) |
|---|---|---|
| Effectiveness | 21.57 ± 24.01 | 11.56 ± 20.70 |
| Side effects | 26.75 ± 35.83 | 13.07 ± 40.19 |
| Convenience | 25.38 ± 20.72 | 10.57 ± 20.93 |
The Beck Depression Inventory (BDI-I) scale was used to measure this outcome. The scale consists of 21 items to assess the intensity of depression in clinical and normal patients. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each item was scored from 0 - 3. If more than one score was provided for an item, the maximum score was considered the item score. The total score was calculated as the sum of all individual items and then compared to a key to determine the depression's severity. The standard key ranges were: 0 - 9 indicated minimal depression; 10 - 18 indicated mild depression; 19 - 29 indicated moderate depression and 30 - 63 indicated severe depression. Higher total scores indicate more severe depressive symptoms.
| scores on a scale | Fingolimod | Standard Disease Modifying Therapy (DMT) |
|---|---|---|
| Change in Patient-reported Depression | -2.88 ± 6.80 | -1.86 ± 8.04 |
The SF-36 is a health-related quality of life instrument used in numerous disease states, including MS (Brazier et al 1992). It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each domain was scored by adding the individual items from the domain and transforming the resulting scores into a 0 to 100 scale with higher scores indicating better health status or functioning.
| scores on scale | Fingolimod | Standard Disease Modifying Therapy (DMT) |
|---|---|---|
| Physical functioning (n=225,61) | 3.62 ± 16.23 | 1.39 ± 14.23 |
| Role limitations due to physical health (n=226,61) | 6.50 ± 21.99 | 4.30 ± 27.52 |
| Bodily pain (n=225,61) | 5.24 ± 23.79 | 0.93 ± 22.95 |
| General health (n=226,61) | 4.28 ± 17.72 | 4.43 ± 22.57 |
| Vitality (n=226,61) | 7.72 ± 18.61 | 1.95 ± 21.97 |
| Social functioning (n=226,61) | 5.59 ± 23.36 | 1.64 ± 23.77 |
| Role limit. due to emotional problems (n=224,61) | 7.18 ± 25.98 | 5.33 ± 27.00 |
| Mental health (n=226,61) | 5.60 ± 18.55 | 2.79 ± 22.09 |
| Physical component summary (n=222,61) | 1.51 ± 5.69 | 0.68 ± 6.57 |
| Mental component summary (n=222,61) | 3.16 ± 9.66 | 1.68 ± 11.31 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod | — | 2/230 (0.9%) | 39/230 (17%) |
| Standard Disease Modifying Therapy (DMT): Interferon Beta-1a | — | 0/28 (0%) | 13/28 (46.4%) |
| Standard Disease Modifying Therapy: Glatiramer Acetate | — | 0/36 (0%) | 10/36 (27.8%) |
| Event | Fingolimod | Standard Disease Modifying Therapy (DMT): Interferon Beta-1a | Standard Disease Modifying Therapy: Glatiramer Acetate |
|---|---|---|---|
| Foot FractureInjury, poisoning and procedural complications | 1/230 | 0/28 | 0/36 |
| Renal colicRenal and urinary disorders | 1/230 | 0/28 | 0/36 |
| Event | Fingolimod | Standard Disease Modifying Therapy (DMT): Interferon Beta-1a | Standard Disease Modifying Therapy: Glatiramer Acetate |
|---|---|---|---|
| Influenza like illnessGeneral disorders | 0/230 | 10/28 | 0/36 |
| Injection site painGeneral disorders | 0/230 | 1/28 | 6/36 |
| LymphopeniaBlood and lymphatic system disorders | 27/230 | 0/28 | 2/36 |
| Injection site erythemaGeneral disorders | 0/230 | 0/28 | 3/36 |
| Alanine aminotransferase increasedInvestigations | 11/230 | 2/28 | 0/36 |
| Gamma-Glutamyltransferase increasedInvestigations | 13/230 | 1/28 | 0/36 |
| Injection site extravasationGeneral disorders | 0/230 | 0/28 | 2/36 |
| Age, Continuous(Years) | Fingolimod | Standard Disease Modifying Therapy (DMT) | Total |
|---|---|---|---|
| Mean | 35.4 ± 9.9 | 36.4 ± 9.3 | 35.6 ± 9.8 |
| Sex: Female, Male(Participants) | Fingolimod | Standard Disease Modifying Therapy (DMT) | Total |
|---|---|---|---|
| Female | 162 | 50 | 212 |
| Male | 68 | 18 | 86 |
The record gives a start of Jan 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod
Multiple Sclerosis, Relapsing-Remitting →